Sonder Capital Closes Second Fund Futures II to Transform Patient Care
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy ISRG?
Source: Newsfilter
- Fund Size and Investors: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Technological Innovation and Impact: The introduction of medical robotics has already transformed operating room procedures, and the addition of AI is set to unlock new levels of performance and automation across care pathways, accelerating a revolution in healthcare systems worldwide that will benefit patients and clinicians alike.
- Team Background and Success Stories: Sonder Capital's team consists of seasoned investors and innovators who have successfully supported numerous companies that have transformed the healthcare industry, including Intuitive Surgical and Shockwave Medical, showcasing their deep expertise in healthcare investment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 469.210
Low
575.00
Averages
637.32
High
740.00
Current: 469.210
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical Continues Robust Growth
- Market Value Insight: Intuitive Surgical boasts a market value nearing $163 billion, and while its shares are currently priced below average, it maintains a dominant position in the robotic surgical systems sector, indicating strong market presence and future growth potential.
- Investment Return Outlook: Investing $1,000 monthly with an assumed annual growth rate of 12% could yield $864,629 after 20 years, suggesting the company has the potential to provide substantial retirement income for investors, especially if it begins paying dividends in the future.
- Valuation Metrics: The current forward P/E ratio stands at 46, which, although high, is lower than the five-year average of 57, indicating relative investment attractiveness, while the price-to-sales ratio of 16.5 is also below the five-year average of 18.4.
- Long-Term Holding Recommendation: Despite potential short-term price fluctuations, purchasing Intuitive Surgical shares now could yield favorable returns for long-term investors, with a strategy of gradually building a position to mitigate risk.
See More
American Airlines Rejects United Airlines Merger Proposal as Anti-Competitive
- Merger Proposal Rejected: American Airlines shares fell in pre-market trading on Monday after firmly rejecting United Airlines' merger proposal, citing significant antitrust hurdles that would give the combined entity a 40% domestic market share, negatively impacting competition.
- Regulatory Scrutiny Pressure: Legal experts suggest that a merger would face unprecedented scrutiny, as the 'Big Four' airlines already control 80% of U.S. capacity, potentially dominating key hubs like Chicago and Dallas by up to 70%.
- Strategic Shift Possible: Despite the rejection, United Airlines may pivot towards smaller acquisitions or asset divestitures to satisfy an administration favoring landmark deals while avoiding concerns over consumer pricing monopolies, thereby maintaining competitive positioning.
- Market Reaction: Following the merger proposal rejection, American Airlines' stock dropped 3.13% and United Airlines' stock fell 3.04%, reflecting market pessimism regarding the merger prospects and potentially influencing future strategic decisions for both companies.
See More
Tesla Set to Report Q1 Earnings Amid Market Surge
- Tesla Earnings Outlook: Tesla is set to report its Q1 fiscal 2026 earnings on Wednesday, with the stock down 11% year-to-date; however, it has shown recovery in April as CEO Elon Musk garners attention for the upcoming SpaceX IPO, and analysts predict profit growth despite vehicle deliveries of 358,000 falling short of the 370,000 expected.
- Terafab Project Acceleration: Musk is urging potential suppliers to expedite the Terafab AI chip-making project, which is estimated to cost over $25 billion and aims to achieve an annual computing capacity of one terawatt, highlighting Tesla's ambitions in the AI sector.
- Market Performance Surge: Despite uncertainties surrounding dealings with Iran, both the S&P 500 and Nasdaq reached new all-time highs, rising 4.5% and 6.8% respectively, while the Dow Jones increased by 3.2%, indicating a robust market recovery.
- Oil Price Impact: Following the U.S. Navy's seizure of an Iranian-flagged ship, benchmark crude prices surged over 6%, with West Texas Intermediate surpassing $88 and Brent crude exceeding $95, which could influence market sentiment.
See More
Intuitive Surgical: Future Investment Potential
- Market Value Growth: Intuitive Surgical boasts a market value nearing $163 billion, and while it currently does not pay dividends, its share repurchases enhance shareholder value, demonstrating a commitment to returns.
- Global Impact: Over 20.4 million patients have undergone procedures with Intuitive systems, which are utilized in more than 70 countries, with over 12,000 systems installed, underscoring its leadership in the robotic surgery sector.
- Strong Financial Performance: The company's latest earnings report revealed a 19% year-over-year revenue increase to $2.9 billion, with procedures growing by 18%, and Ion system procedures surging by 44%, indicating robust product demand.
- Investment Outlook Analysis: Despite a current P/E ratio of 46, below the five-year average of 57, if investors contribute $1,000 monthly with an assumed 12% annual growth, they could accumulate $864,629 in 20 years, highlighting the potential of long-term investments.
See More
Investment Opportunities in Healthcare Stocks
- Market Volatility Impact: The stock market has faced increased volatility recently, with the S&P 500 shifting from gains to losses; although the market has rebounded, many stocks remain at lower valuation levels, reflecting ongoing investor concerns about the economy and interest rate policies.
- Da Vinci Surgical Robot: Intuitive Surgical's Da Vinci surgical robot, priced over $1 million, offers hospitals various options and boasts 150 design innovations and 10,000 times the computing power of its predecessor, helping the company maintain market leadership with a 19% revenue growth in the last quarter.
- Abbott Laboratories Diversification: Abbott Laboratories achieves diversification through its four business units—medical devices, diagnostics, pharmaceuticals, and nutrition—ensuring that when one segment faces challenges, others can provide support, enhancing overall company safety.
- Attractive Dividend Growth: As a 'Dividend King' that has raised its dividend for 50 consecutive years, Abbott's current stock price at 17 times forward earnings, down from 22 times in early 2026, makes it a compelling healthcare stock to invest in following recent market turbulence.
See More
Investment Opportunities in Healthcare Stocks
- Market Volatility Impact: The stock market has experienced volatility recently, with the S&P 500 shifting between gains and losses, leading to increased investor concerns about the economy, interest rates, and geopolitical conflicts, which have dampened stock demand.
- Intuitive Surgical Earnings Growth: Intuitive Surgical (NASDAQ: ISRG) reported a 19% revenue increase and a 17% rise in Da Vinci procedures in the latest quarter, demonstrating its market leadership in robotic surgery and a strong recurring revenue stream.
- Abbott Laboratories Diversification Advantage: Abbott (NYSE: ABT) benefits from its diversified business model across medical devices, diagnostics, pharmaceuticals, and nutrition, which has provided revenue stability, particularly during the pandemic when diagnostics surged to offset declines in medical devices.
- Dividend Growth Appeal: As a
See More
Intuitive Surgical Continues Robust Growth
- Market Value Insight: Intuitive Surgical boasts a market value nearing $163 billion, and while its shares are currently priced below average, it maintains a dominant position in the robotic surgical systems sector, indicating strong market presence and future growth potential.
- Investment Return Outlook: Investing $1,000 monthly with an assumed annual growth rate of 12% could yield $864,629 after 20 years, suggesting the company has the potential to provide substantial retirement income for investors, especially if it begins paying dividends in the future.
- Valuation Metrics: The current forward P/E ratio stands at 46, which, although high, is lower than the five-year average of 57, indicating relative investment attractiveness, while the price-to-sales ratio of 16.5 is also below the five-year average of 18.4.
- Long-Term Holding Recommendation: Despite potential short-term price fluctuations, purchasing Intuitive Surgical shares now could yield favorable returns for long-term investors, with a strategy of gradually building a position to mitigate risk.
See More
American Airlines Rejects United Airlines Merger Proposal as Anti-Competitive
- Merger Proposal Rejected: American Airlines shares fell in pre-market trading on Monday after firmly rejecting United Airlines' merger proposal, citing significant antitrust hurdles that would give the combined entity a 40% domestic market share, negatively impacting competition.
- Regulatory Scrutiny Pressure: Legal experts suggest that a merger would face unprecedented scrutiny, as the 'Big Four' airlines already control 80% of U.S. capacity, potentially dominating key hubs like Chicago and Dallas by up to 70%.
- Strategic Shift Possible: Despite the rejection, United Airlines may pivot towards smaller acquisitions or asset divestitures to satisfy an administration favoring landmark deals while avoiding concerns over consumer pricing monopolies, thereby maintaining competitive positioning.
- Market Reaction: Following the merger proposal rejection, American Airlines' stock dropped 3.13% and United Airlines' stock fell 3.04%, reflecting market pessimism regarding the merger prospects and potentially influencing future strategic decisions for both companies.
See More
Tesla Set to Report Q1 Earnings Amid Market Surge
- Tesla Earnings Outlook: Tesla is set to report its Q1 fiscal 2026 earnings on Wednesday, with the stock down 11% year-to-date; however, it has shown recovery in April as CEO Elon Musk garners attention for the upcoming SpaceX IPO, and analysts predict profit growth despite vehicle deliveries of 358,000 falling short of the 370,000 expected.
- Terafab Project Acceleration: Musk is urging potential suppliers to expedite the Terafab AI chip-making project, which is estimated to cost over $25 billion and aims to achieve an annual computing capacity of one terawatt, highlighting Tesla's ambitions in the AI sector.
- Market Performance Surge: Despite uncertainties surrounding dealings with Iran, both the S&P 500 and Nasdaq reached new all-time highs, rising 4.5% and 6.8% respectively, while the Dow Jones increased by 3.2%, indicating a robust market recovery.
- Oil Price Impact: Following the U.S. Navy's seizure of an Iranian-flagged ship, benchmark crude prices surged over 6%, with West Texas Intermediate surpassing $88 and Brent crude exceeding $95, which could influence market sentiment.
See More
Intuitive Surgical: Future Investment Potential
- Market Value Growth: Intuitive Surgical boasts a market value nearing $163 billion, and while it currently does not pay dividends, its share repurchases enhance shareholder value, demonstrating a commitment to returns.
- Global Impact: Over 20.4 million patients have undergone procedures with Intuitive systems, which are utilized in more than 70 countries, with over 12,000 systems installed, underscoring its leadership in the robotic surgery sector.
- Strong Financial Performance: The company's latest earnings report revealed a 19% year-over-year revenue increase to $2.9 billion, with procedures growing by 18%, and Ion system procedures surging by 44%, indicating robust product demand.
- Investment Outlook Analysis: Despite a current P/E ratio of 46, below the five-year average of 57, if investors contribute $1,000 monthly with an assumed 12% annual growth, they could accumulate $864,629 in 20 years, highlighting the potential of long-term investments.
See More
Investment Opportunities in Healthcare Stocks
- Market Volatility Impact: The stock market has faced increased volatility recently, with the S&P 500 shifting from gains to losses; although the market has rebounded, many stocks remain at lower valuation levels, reflecting ongoing investor concerns about the economy and interest rate policies.
- Da Vinci Surgical Robot: Intuitive Surgical's Da Vinci surgical robot, priced over $1 million, offers hospitals various options and boasts 150 design innovations and 10,000 times the computing power of its predecessor, helping the company maintain market leadership with a 19% revenue growth in the last quarter.
- Abbott Laboratories Diversification: Abbott Laboratories achieves diversification through its four business units—medical devices, diagnostics, pharmaceuticals, and nutrition—ensuring that when one segment faces challenges, others can provide support, enhancing overall company safety.
- Attractive Dividend Growth: As a 'Dividend King' that has raised its dividend for 50 consecutive years, Abbott's current stock price at 17 times forward earnings, down from 22 times in early 2026, makes it a compelling healthcare stock to invest in following recent market turbulence.
See More
Investment Opportunities in Healthcare Stocks
- Market Volatility Impact: The stock market has experienced volatility recently, with the S&P 500 shifting between gains and losses, leading to increased investor concerns about the economy, interest rates, and geopolitical conflicts, which have dampened stock demand.
- Intuitive Surgical Earnings Growth: Intuitive Surgical (NASDAQ: ISRG) reported a 19% revenue increase and a 17% rise in Da Vinci procedures in the latest quarter, demonstrating its market leadership in robotic surgery and a strong recurring revenue stream.
- Abbott Laboratories Diversification Advantage: Abbott (NYSE: ABT) benefits from its diversified business model across medical devices, diagnostics, pharmaceuticals, and nutrition, which has provided revenue stability, particularly during the pandemic when diagnostics surged to offset declines in medical devices.
- Dividend Growth Appeal: As a
See More
